NeuroPace (NPCE) Return on Capital Employed (2021 - 2026)
NeuroPace (NPCE) recorded quarterly Return on Capital Employed of 19.47% in Q1 2026, down 5.6% quarter-over-quarter from 18.44% in Q4 2025, and up 250.0% on a YoY basis from 5.56% in Q1 2025.
NeuroPace (NPCE) Return on Capital Employed (2021 - 2026) Analysis & Trends
NeuroPace's Return on Capital Employed history runs 6 years deep, the most recent figure standing at 19.47% for Q1 2026.
- In Q1 2026, Return on Capital Employed rose 250.0% year-over-year to 19.47%; the TTM figure through Mar 2026 stood at 19.47% (up 250.0% YoY), while the FY2025 annual figure was 19.85%, up 535.0% from the prior year.
- Return on Capital Employed was 19.47% for Q1 2026 at NeuroPace, down from 18.44% in the prior quarter.
- In the past five years, Return on Capital Employed ranged from a high of 18.44% in Q4 2025 to a low of 39.23% in Q1 2023.
- Historically, Return on Capital Employed has averaged 29.08% across 5 years, with a median of 29.29% in 2024.
- The sharpest annual moves came in 2022 and 2024: Return on Capital Employed tumbled 2322 bps in 2022, then soared 994 bps in 2024.
- A 5-year view of Return on Capital Employed shows it stood at 38.37% in 2022, then gained by 19 bps to 31.15% in 2023, then grew by 13 bps to 26.98% in 2024, then soared by 32 bps to 18.44% in 2025, then declined by 6 bps to 19.47% in 2026.
- The last three Return on Capital Employed figures came in at 19.47% (Q1 2026), 18.44% (Q4 2025), and 20.93% (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 154.42 Bn | 147.76 Bn | 6.27 Bn | 9.61% |
| 2 | Stryker | 118.12 Bn | 115.25 Bn | 3.81 Bn | 12.24% |
| 3 | Medtronic | 101.72 Bn | 93.55 Bn | 5.76 Bn | 7.36% |
| 4 | Boston Scientific | 67.19 Bn | 65.98 Bn | 3.61 Bn | 9.62% |
| 5 | Edwards Lifesciences | 50.69 Bn | 47.02 Bn | 1.29 Bn | 11.13% |
| 6 | Koninklijke Philips | 29.38 Bn | 26.07 Bn | 2.07 Bn | 10.45% |
| 7 | Dexcom | 28.09 Bn | 26.97 Bn | 750.30 Mn | 24.24% |
| 8 | GE HealthCare Technologies | 28.08 Bn | 26.02 Bn | 1.98 Bn | 9.30% |
| 9 | Steris | 19.80 Bn | 19.37 Bn | 697.10 Mn | 11.57% |
| 10 | NeuroPace | 527.50 Mn | 473.52 Mn | 18.05 Mn | -19.47% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -19.47% |
| Dec 31, 2025 | -18.44% |
| Sep 30, 2025 | -20.93% |
| Jun 30, 2025 | -21.83% |
| Mar 31, 2025 | -21.97% |
| Dec 31, 2024 | -26.98% |
| Sep 30, 2024 | -28.63% |
| Jun 30, 2024 | -29.48% |
| Mar 31, 2024 | -29.29% |
| Dec 31, 2023 | -31.15% |
| Sep 30, 2023 | -36.36% |
| Jun 30, 2023 | -39.07% |
| Mar 31, 2023 | -39.23% |
| Dec 31, 2022 | -38.37% |
| Sep 30, 2022 | -36.29% |
| Jun 30, 2022 | -32.03% |
| Mar 31, 2022 | -24.85% |
| Dec 31, 2021 | -18.53% |
| Sep 30, 2021 | -13.07% |
| Jun 30, 2021 | -13.87% |